Otsuka (OTCMKTS:OTSKY) Stock Gets Downgrade from Zacks Research

Otsuka (OTCMKTS:OTSKY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.

Otsuka Trading Down 1.0%

OTCMKTS OTSKY opened at $37.68 on Monday. The business’s fifty day moving average is $37.29 and its 200-day moving average is $35.15. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.21 and a quick ratio of 1.65. The stock has a market capitalization of $40.48 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 2.75 and a beta of 0.08. Otsuka has a one year low of $26.11 and a one year high of $40.92.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Friday, October 30th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. The firm had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.42 billion. Equities research analysts predict that Otsuka will post 2.21 EPS for the current year.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.